QNTM Quantum Biopharma Ltd.
Price Chart
Executive Summary
Quantum Biopharma Ltd. (QNTM) announced the submission of an Investigational New Drug (IND) application to the FDA for its Lucid-MS candidate, targeting a Phase 2 clinical trial in multiple sclerosis. This marks a key advancement in its clinical pipeline, with FDA feedback expected in Q2 2026 and trial initiation planned shortly thereafter.
Actionable Insight
Monitor for FDA feedback in Q2 2026, which will determine Phase 2 trial initiation. Positive clearance could catalyze investor interest given the first-in-class mechanism and unmet need in MS. Watch for interim Phase 2 data in Q4 2026 as a key value inflection point.
Key Facts
- Submitted IND application to the FDA for Lucid-MS, a first-in-class therapeutic targeting demyelination in multiple sclerosis.
- Phase 1 trials completed with favorable safety and tolerability profile in healthy participants.
- Anticipated FDA response in Q2 2026, with Phase 2 trial initiation planned in Q2 2026 and interim data projected for Q4 2026.
- Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
- Company retains 19.84% ownership in Unbuzzd Wellness Inc. and a 7% royalty on sales until $250 million is paid, then 3% in perpetuity.
Financial Impact
No direct financial figures disclosed. Potential long-term value from successful clinical development in a $38B global MS market by 2030.
Risk Factors
- FDA may not clear the IND, delaying or halting clinical development.
- Phase 2 trial may fail to demonstrate efficacy or safety despite positive Phase 1 results.
- Low market cap ($28M) increases volatility and susceptibility to dilution in future funding rounds.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002144 |
| Document: f6k_033126.htm | 0001171843-26-002144 |
| Document: 0001171843-26-002144-index-headers.html | 0001171843-26-002144 |
| Document: 0001171843-26-002144-index.html | 0001171843-26-002144 |
| Document: 0001171843-26-002144.txt | 0001171843-26-002144 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
7d ago
|
6-K
| $5.11 $4.88 | ▲ +4.50% | ▲ +3.81% | $4.05 (+20.74%) |
|
Jun 2, 2026
7d ago
|
6-K
| $5.11 $4.88 | ▼ −4.50% | ▼ −3.78% | $4.05 (−20.74%) |
|
May 18, 2026
22d ago
|
6-K
| $6.27 $7.00 | ▲ +11.64% | ▲ +12.29% | $4.05 (−35.41%) |
|
Apr 22, 2026
6w ago
|
6-K
| $3.35 $3.21 | ▼ −4.18% | ▼ −3.79% | $4.05 (+20.90%) |
|
Apr 22, 2026
6w ago
|
Press Release
| $3.35 $3.21 | ▼ −4.18% | ▼ −3.79% | $4.05 (+20.90%) |
|
Apr 2, 2026
9w ago
|
6-K
| $3.98 $3.58 | ▼ −10.05% | ▼ −10.53% | $4.05 (+1.76%) |
|
Apr 1, 2026
9w ago
|
6-K
| $4.41 $3.98 | ▼ −9.75% | ▼ −9.83% | $4.05 (−8.16%) |
|
Apr 1, 2026
9w ago
|
Press Release
| $4.41 $3.98 | ▼ −9.75% | ▼ −9.83% | $4.05 (−8.16%) |
|
Mar 30, 2026
10w ago
|
Court Ruling
| $4.28 $4.83 | ▲ +12.85% | ▲ +9.96% | $4.05 (−5.37%) |
|
Mar 27, 2026
10w ago
|
6-K
| $4.77 $4.28 | ▼ −10.27% | ▼ −9.91% | $4.05 (−15.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access